Carboplatin-based combination chemotherapy for testicular cancer relationship among administration dose of carboplatin, renal function and myelosuppression

Carboplatin-based combination chemotherapy for testicular cancer : relationship among administration dose of carboplatin, renal function and myelosuppression

Carboplatin (CBDCA), a derivative of cis-diamminedichloroplatinum, has low renal and neural toxicity. The dose-limiting factor of this agent is myelosuppression. We experienced various degrees of myelosuppression, when the dose of CBDCA was determined by the body surface area (BSA) in CBDCA-based co...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 41(1995), 10 vom: 29. Okt., Seite 775-80
1. Verfasser: Suzuki, K (VerfasserIn)
Weitere Verfasser: Matsumoto, K, Hashimoto, K, Kurokawa, K, Jinbo, S, Suzuki, T, Imai, K, Yamanaka, H, Kawashima, K, Takahashi, H
Format: Aufsatz
Sprache:English
Veröffentlicht: 1995
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial Journal Article Carboplatin BG3F62OND5